Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier® ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...